story of the week
Safety/Efficacy of BTK Inhibitor Tolebrutinib in Relapsing MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Tolebrutinib, an Oral Brain-Penetrant BTK Inhibitor, in Relapsing Multiple Sclerosis: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Trial
Lancet Neurol 2021 Sep 01;20(9)729-738, DS Reich, DL Arnold, P Vermersch, A Bar-Or, RJ Fox, A Matta, T Turner, E Wallström, X Zhang, M Mareš, FA Khabirov, A TraboulseeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.